oelb bwe been fix& to be am&bk to tbe (Table 1) . 
e n -d l t o t h a t d -a k -t h a t
caseofpuamyx~virus,couMbethefitPion~forHIVon some cells.
Thus,tbepropoaeduseofsCD4toblocktheextestofvinW
idkction and its spread in the host (13) warronto furibaevaluationIntl$smgan-l,freJbvinisisdatesfrominfbctedindividuals iavdws one portion of gp120 (including the V3 region), whereas U937 and CEM infection involve another (Fii 2) (45). The l a t e Dbservation supports the conclusion that the U937 monocytic o e l l l i w k e o t & R W o a e t o~I t i w b o s t t~l g e n t l l n i t r d PeriPheralM~marrophages.
a p p t a r t a b e l c P s~y c t o~t h o n s t a t r d a r d l a b a r a t o r y ~( 1 4 ) . T h e~c o u l d b e a p a t e r a f f m i t y o f t h e f n s h v h u s i o o l o t e g f a a t h e C W p a a r e n t o n C D 4 +~

cdldeath(23).Neverthelese,thefirnctionoftheseaItsismoJt W y a ,~k 5 a n y i m m~d i s o t d a s h a v e b e a r ~beflinHIVinf~endsuecansidasdthtreasonforthe infections d ma@mwh that develop with AIDSYcttBcwayinwlSichtheveYsspacificallyafttctstheT ~~o r s k r l n m n t o d t i c t t h n # m~c a t i 0 n s i
y p o t e a a i n d~t h o a # c i t e d f o r t h e C N S : d i n d~o f b o w d~r a d~d e c t o f t o x l c c d h ; l l r r a r~& 1 E t o n (19b
In most ncent studies, Tatsuo Shioda and our group have demonstrated that as few as three amino acid changes in the V3 loop can convert a Td-tropic virus into a macrophage-tropic virus (unpublished observations) . Moreover, only one amino acid change in the V3 loop can eliminate the ability of a virus to infect a T-cell line (e.g. . These observations are dramatic and emphasize how very small changes in the HIV envelope i l + might influence relative infection rates and spread in a host. Nevertheless, most data suggest that many amino acid changes are required to cause major alterations in the tropism of the virus, and some of these are not linked but appear in regions outside the V3 loop (unpublished observations, 47).
The domain correlating with enhanced cytopathology has been found in some studies within the same envelope portion as the (49, 50) .
a&& ~t i c~t a t i o n o f t b e v i n l g e n o m e~d c a a -
The latter concept was proposed after observing that when the nqfgene is deleted from a viral DNA clone, the d t i n g infectious HIV replicates to much higher titer and is more cytopathic than the parental strain (49). These findings suggmed that the Nef protein suppresses virus replication and thus could be responsible for a "silent" state. This hypothesis has received support from the observations by Cheng-Mayer et al. (5 1) that when the Nef protein is introduced by molecular techniques into T-cell lines, HIV-1 replication can be suppmsed, although virus entry and integration take place. A notable finding has been that the more cytopnthic viruSes are resistant to the effects of Nef (5 1).
Thus, viruses isolated early h m a healthy individual show a sensitivity to Nef, whereas viruses recovered later, when the same individual has AIDS, arc resistant to the suppressive effects of the Nef protein (Table 3) . strains, whenas they m a y have neutralizing a n t i i y to the strain used for immunization (58). Finally, some sera from infected individuals can show neutralidng activity againsi one strain (e.g.
H I V -1~) but enhanment of another (e.g. HIV-lsplm) (58).
It is noteworthy, as demonstrated rcantly by Kliks er uf. (59), that the same MAb can show neutralizing or enhancing activity, depending on the HIV-1 strain used. Very small changes within the V3 loop can determine whether a virus is neutralized or enhanced by a W c u l a r antibody species (59). This observation suggtsts ways in which the virus could escape an immune response of the host. A small amino acid change might determine the dative sensitivity to neutralization by an antibody and thus the pathogenicity of the viral strain.
The enhancing antibodies not only increase infection of mae rctpbgfs, but also CD4+ lymphocytes and even fibroblasts (56). In some casw, the CD4 molecule is involved (60,61); in others, it is not (56). This points out the need for another caution about the universal use of sCD4. The envelope region responsible for ADE appears to be located within a120 for the Femediated nsponse (59) and within gp41 for the complement-mediated activity (62). Additional work should define distinct epitopes. The mechanism for this CD8+ cell activity involves, in part, a cellular tictor that s u p p~ HIV-1 replication in culture without killing the cell (7 1). Most recent studies indicate that the cellular factor is a novel cytokine that has no relationship to any of the known antivhd fitcton, including the int&rons and tumor necrqsis factor (52). The m e d u m b of action also appears to be distinct from that of these agents. The CD8+ cell hctor suppresses virus RNA tramcription after viral integration (72). We believe this cellular immune response is very important in controlling HIV infection. In this regard, long-term survivors have very strong CD8+ cell-suppressing activity.
Autoimmunity. One other aspect of the immune response in HIV infection is the production of autoantibodies that may be diffcted to various cellular proteins (9). These can give rise to autoimmune diseases inducing neutropenia, thrombocytopenia, and peripheral neuropathy ( " s i l e a t "~s t a 0 e .
As physicians and basic reseamhers directing our efforts to finding a solution to the problem of AIDS, we must recognize that attacks on the virus itself or approaches to enhance the immune response of the host against HIV can be helpful in delaying the progression to disease or even completely arresting 9 the viral infection. Many antiviral drugs have been developed, but they work primarily against reverse tramcriptase (76). Thus, those products would limit the early steps in virus infection but not affect the virus-infected cells. Thus far, only t r i m t h i n (7' appears to act selectively against HIV-infected cells, but th observation and its clinical relevance require W e r study No drug has yet been found to induce a strong cellular immune response against the virus. These thetapies are needed Recmtly, postinfection vaccination with the viral envelope gpl60 has been suggesSed as a method for enhancing the immune respbnse (78). This possibility also requires further evaluation and confirmation. a
4
Our laboratory is dincting its efforts at determinid whher the Nef protein (after puri!ication) can be used early in infection to block the replication of the relatively nonpathogenic strain so that it would not go through further replicative cycles tQ eneerge as a "virulent" strain. We are also directing our efforts at defining the CD8+ cell Eactor with hopes that its purification in the laboratory or its & novo synthesis in vivo might lead to efhtive antiviral therapy. In this regard, approaches that could induce strong CD8+ cell-suppressing activity in the host merit much additional attention, but, as noted above, &Wive e f k t s on the cellular immune w n s e have not yet been obscmed With any immune-modulating drugs.
WhatisdearfromtheseandothershrdirsinourlaboratDlyi)
that long-term survivors-indivkiwb living more than 8 y (some for as long as 13 y) rfta infkdh, with normal CW+ d counts-have chmadda expaW of a beahhy oarrig. l E q exa virus that is nktively nonpathogenic, have a stroq CD8+ cell antiviral mpame, and do not produT b e ) . s & o u M b e~~t h o r c~n s t b a t m a y e n - hance Virus i n f h through the ADE mc~hadm. T h a a n -
~e x t c n s i v c~o f i n c t i n ' r d u o b w i t h m o d e l w E c i n c d ~c o n s i d e r t h e~c i a i~o f~~
a n t i~i n t h e l m t , z i s w e l l a s a~u n c~c n a t h P t rcsultfirom~nsestovifalprotdnstbatamdurrtdbynormPl Qdlular components the hut /73,74,79j.
We have come a long way in our attack on HIV since it ernaged as a major infkUb in the early 1980s Extensive infixmation about the biology, mmokcuIar biology, and immunology of HIV infection is known, but many mysteries d.
C ! b h g m to the scientific community include iden* the mqjor cause of the loss of CD4+ lymphocytes in the Mood, umbmtadng the d o e y of ncurdogic symptoms in the host, and deh& the variety ofhctm that pcamit loqt-tcnn survival in some inkted iadividuals (19). Answen to thae and ather questions will mtually become known, and appropriate therapies will be f d Howeret, H W is a aoving m" and unless support, both financial and scien-is continually available, AIDS will equal the other major epidemics that have hit and devastated global jmpulati~ll~ ihughout history. . . antibodies=
IgG. W c h v e n o t b e e n a b k t o~t h c m y e t i n t o s u~
to sm if thcn will be a clistb&n. We would like to do that. As
toyaursecoadpoht,one~bkdr~enheaaementhCW+ c d f s w k b I g C i . W e b a v e b e c m t d d b y~o a E c~ t k a t t t r e n i s~a n F~~n a p t o r o n T l y m p h o c y b e s , a n d
thet f the receptm involved.
D r .~~T h a t L i s t p o i n t i s c o n t r o~i n t e r m s o f wbetbaoawttheneisanFcrecqrtormT-
I w o u l d l i k e t o~o n t b h~~p m p e r t y . 
W e c a n s e e~w i t h s i m i l a r~t y , t o t h e t h e m o k c u I c ,
i g b -a t f i n i t y n e u~a n t i b o d y t o~@~a nti-
in this one patient? Dr. Levy: First, one must nmgnke. that the virus is also evolving. Until we can look at the a f b t y of the a n t i i y to a p.ticular virus, we will not know the answer. But we have seen this type of mspome in three of five individ* the a n t i i has changed In some cases the virus has cbgcd. The dynamics depend on thost two pouameten. One cannot just say that over time there should be bttter llcumlhatim. In regad to your other poist, one of my amcans with w k l e s p d vaccination is t h s t t h e i m m u n e~n s c m i g h t b e~m t h e w n , n g w a y . 
